UnitedHealth Group IncorporatedNYSE: UNH
Health Care · Managed Health Care
$370.09
-0.11%
Vol: 5.0M
Research Digest
Friday, May 1, 2026
UnitedHealth Q1 2026 EPS beat ($7.23 vs $6.59) with strong medical cost discipline; raised FY guidance; stock up 14.5% post-earnings
UnitedHealth reported Q1 2026 adjusted EPS of $7.23, beating estimates of $6.59 by 9.7%, with revenues of $111.7B exceeding $109.44B forecast. Medical benefit ratio came in at 83.9% vs 85.5% forecast, showing strong cost discipline. Management raised full-year 2026 adjusted EPS guidance to >$18.25 from >$17.75. Stock surged 14.5% post-earnings and up 37% past month on results and favorable Medicare Advantage rate outlook. JPMorgan raised PT to $420 from $389. Company investing $1.5B in AI during 2026.
Previous Market Intelligence
13 daysApr 30JPMorgan upgrades UNH to $420 PT after Q1 earnings beat with 9.7% EPS outperformance and improved medical benefit ratioPositive▶
UnitedHealth reported strong Q1 2026 results with adjusted EPS of $7.23 exceeding consensus of $6.59 and revenue of $111.7B surpassing $109.44B expectations. JPMorgan raised its price target to $420 from $389, while Erste Group upgraded from Hold to Buy. Cost discipline drove the beat with medical benefit ratio at 83.9% versus 85.5% forecast. Management raised full-year 2026 guidance to greater than $18.25 per share from $17.75 and authorized $2B+ buyback completion by Q2 2026. The stock reflects healthy fundamentals despite regulatory pressures on insurance consolidation.
Apr 29UNH Beats Q1 Earnings with 9.7% EPS Surprise; JPMorgan Raises PT to $420Positive▶
UnitedHealth Group posted Q1 2026 adjusted EPS of $7.23, beating consensus by 9.7%, and revenue of $111.7B exceeded expectations. Management raised full-year 2026 adjusted EPS guidance to >$18.25/share from >$17.75/share. JPMorgan upgraded to $420 PT from $389, while Erste Group upgraded to Buy from Hold. Medical benefit ratio came in at 83.9% vs. 85.5% forecast, benefiting from favorable Medicare Advantage policy. Stock up 3.4% on analyst upgrade and strong earnings.
Apr 16UnitedHealth surged up to 10% on April 11 after U.S. approved 2.48% increase in 2027 Medicare Advantage rates; earnings report scheduled for April 21Positive▶
UnitedHealth rallied sharply following U.S. approval of 2.48% 2027 Medicare Advantage rate increase on April 11, with intraday gains up to 10%, marking the largest single-day move since August 2025. HSBC upgraded from reduce to hold with $300 price target on April 7, while BofA raised price targets signaling improved fundamentals outlook. The company will release Q1 2026 results on April 21 before market open, a critical juncture after UNH fell 54% from 52-week high and is down 45.5% year-over-year. Analysts maintain consensus price target of $357.81 versus current $282.33, implying meaningful upside if recovery story validates.
Apr 15UnitedHealth Group surges on favorable Medicare Advantage rate increase of 2.48% for 2027, boosting growth prospectsPositive▶
UnitedHealth Group stock surged on 2.48% increase in average Medicare Advantage payments for 2027, translating to over $13 billion in additional funding. Raymond James upgraded to Outperform with $330 target. Stock has fallen 54% from 52-week high but holds Strong Buy consensus with average target of $366.47. Q1 earnings scheduled April 21.
Apr 14UnitedHealth surges 10% on 2.48% Medicare Advantage rate increase; deploying AI assistant to 20M membersPositive▶
Received 2.48% Medicare Advantage rate increase for 2027 (~$13B industry impact). Stock surged 10%. Deploying Avery AI assistant to 20M+ members via $1.6B AI investment. Q1 earnings April 21.
Apr 13UnitedHealth surges 10% on Medicare Advantage rate hike; Q1 earnings April 21Positive▶
UnitedHealth Group stock jumped 10% (largest intraday move since August) on April 6-7 after U.S. raised 2027 Medicare Advantage payment rates by 2.48%, adding $13B+ to insurers. Addresses years of cost pressures. Q1 earnings release April 21 before market open. Ongoing DOJ criminal/civil investigations into Medicare billing practices remain unresolved. CEO reaffirmed 13-16% long-term earnings growth target.
Apr 10UnitedHealth surges 9.4% on 2.48% Medicare Advantage rate increase; Q1 earnings April 21.Positive▶
UnitedHealth shares surged 9.4% following announcement of 2.48% Medicare Advantage rate increase for 2027, exceeding initial proposals and providing over $13B in additional funding. Company investing $3B in AI with 22,000 software engineers. UnitedHealth fell 54% from prior highs. Q1 2026 earnings scheduled April 21. Consensus rating is Buy with $377.83 target (23% upside).
Apr 9UnitedHealth Surges 8% on 2.48% Medicare Advantage Rate Increase for 2027Positive▶
UnitedHealth Group jumped nearly 8% after the Centers for Medicare & Medicaid Services finalized a 2.48% increase in 2027 Medicare Advantage reimbursement rates, worth $13 billion industry-wide. The upgrade addresses industry concerns about flat rates proposed in January. UnitedHealth carries a Strong Buy consensus (18 Buys, 4 Holds) and will report Q1 FY2026 results on April 21.
Apr 8UnitedHealth soars 9.81% on 2.48% Medicare Advantage rate increase; Bernstein raises PT to $411.Positive▶
CMS finalized 2027 Medicare Advantage payment increase of 2.48% (over $13B industry-wide), a major relief from January's 0.09% guidance. UNH jumped from $281.36 to $311, up nearly 11%, easing margin squeeze concerns. Bernstein raised price target to $411 from $405. Raymond James upgraded to Outperform with $330 target.
Apr 7UnitedHealth jumps 8-9.6% after CMS announces 2.48% Medicare Advantage rate increase for 2027.Positive▶
UnitedHealth shares surged 8-9.6% to $303 after CMS finalized 2.48% Medicare Advantage rate increase for 2027, adding ~$13 billion in additional payments. Raymond James upgraded UNH to Outperform from Market Perform with $330 price target, arguing Street underestimates earnings power. Q1 FY2026 earnings due April 21 (Street expects 8% YoY EPS decline to $6.65 due to higher Medicare costs). Consensus Strong Buy from 17 Buy, 4 Hold, 0 Sell. Analysts estimate 32% upside. Company faces DOJ probe of Optum division and antitrust litigation on insulin pricing. Over past year, UNH down 46.98%. Stock now $303.
Apr 6Raymond James upgrades UnitedHealth to Outperform with $330 PT on Optum margin visibility.Positive▶
Raymond James upgraded UNH to Outperform from Market Perform with $330 PT. Driven by Optum margin improvement visibility and multibillion-dollar AI spend (Avery generative AI claims platform). Stock up 1.25% on upgrade. Q1 earnings April 21. 20 Strong Buy ratings (~32% upside).
Apr 3Raymond James upgrades UNH to Outperform with $330 target; earnings report due April 21 as Medicare headwinds persist.Mixed▶
Raymond James upgraded UnitedHealth from Market Perform to Outperform on April 2 with $330 price target, though the stock remains down nearly 50% over the past year. UNH faces significant challenges: medical care ratio reached 88.9% due to CMS Medicare funding cuts and rising costs. The company announced new leadership for health insurance arm. Q1 2026 earnings report scheduled for April 21. DOJ investigation ongoing.
Apr 1UnitedHealth Group adds former FDA chief Scott Gottlieb to board; Q1 2026 earnings scheduled April 21 with 33.9% upside potential.Mixed▶
UnitedHealth Group will release Q1 2026 financial results on Tuesday, April 21, 2026 before market open. Dr. Scott Gottlieb, former FDA commissioner, joined the board effective immediately. UnitedHealthcare introduced Avery, a generative AI healthcare companion rolling out across commercial plans. Despite recent 48.3% stock decline over the past year due to legal challenges and regulatory scrutiny, consensus remains Moderate Buy with 33.9% upside and average 12-month price target of $387.79.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| UNHUNITEDHEALTH | $370.09 | -0.11% | +31.7% | 17.9x | 0.41 | $336.5B |
| ELVELEVANCE | $373.38 | -0.81% | +24.4% | 12.9x | 0.50 | $81.7B |
| HUMHUMANA | $234.67 | -0.75% | +29.4% | 15.5x | 0.45 | $28.4B |
| CNCCENTENE | $53.45 | -0.45% | +51.7% | 12.3x | 0.59 | $26.5B |
| MOHMOLINA | $192.82 | -0.92% | +35.8% | 21.9x | 0.55 | $10.1B |
| LLYELI | $964.50 | +3.20% | +0.8% | 22.2x | 0.50 | $834.9B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.